Suppression of puerperal lactation by terguride: A double-blind study

P. L. Venturini, R. Horowski, V. Fasce, M. Valenzano, C. Ferreri, G. Badino, E. Rainer, A. Scholz, L. De Cecco

Research output: Contribution to journalArticlepeer-review


Clinical efficacy, prolactin (PRL)-lowering effect and tolerance of terguride (an 8-alpha-ergolinc derived from Lisuride which acts as a partial dopaminergic agonist) were investigated in a double-blind study on inhibition of puerperal lactation using three different daily doses of the drug (0.25, 0.5 and 1.0 mg). With 0.5 and 1.0 daily therapeutical regimens PRL levels were suppressed in a dose-dependent manner and lactation was prevented. Terguride was highly well tolerated.

Original languageEnglish
Pages (from-to)33-38
Number of pages6
JournalGynecologic and Obstetric Investigation
Issue number1
Publication statusPublished - 1988


  • Dopaminergic agonists
  • Inhibition of lactation
  • Terguride

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine


Dive into the research topics of 'Suppression of puerperal lactation by terguride: A double-blind study'. Together they form a unique fingerprint.

Cite this